Table 15Summary of the Stepped Analysis of the CADTH Exploratory Analysis Results

Stepped analysis Drug Total costs ($) Total QALYs ICER ($/QALY)
Sponsor’s base casea,bCarboplatin + paclitaxelc61,3601.52Reference
Dostarlimab865,8636.42164,193
CADTH reanalysis 1dCarboplatin + paclitaxelc61,3881.51Reference
Dostarlimab513,0502.49460,362
CADTH reanalysis 2Carboplatin + paclitaxelc61,3881.51Reference
Dostarlimab867,9132.12179,306
CADTH reanalysis 3Carboplatin + paclitaxelc61,3881.51Reference
Dostarlimab505,2436.1296,172
CADTH reanalysis 4Carboplatin + paclitaxelc61,3881.51Reference
Dostarlimab671,5293.33333,955
CADTH exploratory analysisa,dCarboplatin + paclitaxelc61,6981.54Reference
Dostarlimab436,4862.65$336,627

ICER = incremental cost-effectiveness ratio; QALY = quality-adjusted life-year.

a

The sponsor’s and CADTH base case results are probabilistic while remaining analyses are deterministically presented.

b

Reference product is the next most efficacious comparator based on the results of sponsor’s submitted indirect treatment comparison, and the best survival evidence from the RWE data.

c

Sponsor’s submitted base case: dostarlimab vs. carboplatin + paclitaxel only.

d

Probabilistic results are presented for the CADTH exploratory reanalysis, which includes key limitations identified by CADTH that were modifiable in the sponsor’s economic model. All other analyses are presented deterministically.

From: Pharmacoeconomic Review

Cover of Dostarlimab (Jemperli)
Dostarlimab (Jemperli): CADTH Reimbursement Review: Therapeutic area: Endometrial cancer [Internet].
Copyright © 2022 Canadian Agency for Drugs and Technologies in Health.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.